Novavax earns $125 mln milestone as Sanofi launches Phase 3 flu-COVID combo vaccine trial in Europe
Novavax said it earned a $125 mln milestone payment after the fifth patient was dosed in Sanofi's Ph
Novavax said it earned a $125 mln milestone payment after the fifth patient was dosed in Sanofi's Ph